Leptin in Human Energy and Neuroendocrine Homeostasis

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Rudolph L. Leibel, Columbia University
ClinicalTrials.gov Identifier:
NCT00265980
First received: December 14, 2005
Last updated: July 31, 2012
Last verified: July 2012
  Purpose

Previous work in our laboratory, and many others, has shown that body weight is regulated. When anyone, fat or thin, tries to maintain a reduced body weight, many systems affecting energy balance (skeletal muscle, neuroendocrine, and autonomic systems) conspire to slow metabolic rate thus favoring the regain of lost weight. Individuals with leptin deficiency are remarkably similar to weight-reduced individuals. Their metabolism, thyroid hormones, and sympathetic nervous system activity are all low despite their obesity. While administration of leptin to leptin-deficient humans results in substantial weight loss and increases in energy expenditure. However, leptin administration to leptin-sufficient humans at usual body weight has little or no effect on weight unless given in doses 10-20 times what would be considered to be in the normal physiological range. This study examines the hypothesis that leptin is "read" by various systems regulating energy balance as an indicator of how much energy we have stored and that the body perceives the weight-reduced state as a condition of relative leptin insufficiency. Within this model, restoration of leptin to levels present prior to weight loss should relieve much of the metabolic opposition to keeping weight off. Preliminary studies support this hypothesis.

Healthy lean and overweight subjects are admiited to the General Clinical Research Center at Columbia University Medical College and placed on a liquid formula diet. Calories are adjusted until weight is stable and then subjects undergo testing of neuroendocrine, autonomic, and metabolic function. All subjects undergo an in-patient 10% weight reduction. Subjects are studied in a single blind placebo control design in which they are studied at usual weight and while maintaining a 10% reduced weight. At either usual weight or reduced state subjects undergo a single blind crossover placebo/control study in which they receive placebo,lepin injections while on an isocaloric diet either at usual weight or following a 10% weight loss. Leptin injections are given in doses that restored 8AM circulating leptin concentrations to those present at initial body weight.


Condition Intervention
Obesity
Weight Loss
Drug: Placebo
Drug: Leptin
Drug: placebo
Drug: Tri-iodothyronine

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Leptin in Human Energy and Neuroendocrine Homeostasis

Resource links provided by NLM:


Further study details as provided by Columbia University:

Primary Outcome Measures:
  • Reversal of metabolic changes associated with maintenance of a reduced body weight. [ Time Frame: End of study ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: July 2002
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: A
Subjects undergo studies at their usual body weight
Placebo Comparator: B -1
Subjects are studied while at a 10% reduced body weight and receiving twice daily injections of placebo for 5 weeks
Drug: Placebo
twice daily iinjections of saline in the same volume as will be used for B-2 leptin injections
Experimental: B-2
Subjects are studied while at a 10% reduced body weight and receiving twice daily injections of "replacement" leptin for 5 weeks
Drug: Leptin
Leptin will be given as twice daily subcutaneous injections in doses titrated to replicate 8AM circulating leptin concentrations measured in the same subjects prior to weight loss.
Placebo Comparator: C-1
Subjects are studied while at a 10% reduced body weight and receiving an oral placebo for 5 weeks
Drug: placebo
Subjects will receive a once daily oral placebo
Experimental: C-2
Subjects are studied while at a 10% reduced body weight and receiving an oral "replacement" of thyroid hormone for 5 weeks
Drug: Tri-iodothyronine
Subjects will receive a once daily oral dose of T3 which will be titrated until 8AM T3 levels are similar to those measured in the same subjects prior to weight loss.
Other Name: Cytomel

Detailed Description:

The failure of obesity treatments to sustain weight reduction is widely recognized. The central hypotheses of these studies are that: 1.) Energy and neuroendocrine homeostastic systems are altered during the maintenance of a reduced body weight in a manner that favors weight regain; 2.) These changes occur because weight-reduced individuals are in a state of relative leptin deficiency due to loss of body fat; and 3.) Therefore these changes accompanying the maintenance of a reduced body weight will be reversed if circulating leptin concentrations are restored to those that were present prior to weight reduction.. Maintenance of a reduced body weight is associated with integrated autonomic and neuroendocrine changes that reduce energy expenditure and increase food intake in a manner that is similar to that seen in rodents and humans who are deficient in, or resistant to, the adipocyte-derived hormone leptin. Systemic leptin administration to leptin-deficient rodents and humans reverses the metabolic (hypometabolism, hyperphagia), autonomic (increased parasympathetic and decreased sympathetic nervous system tone), and neuroendocrine (increased hypothalamic-pituitary-adrenal axis activity, decreased hypothalamic-pituitary -thyroidal and -gonadal axis activity) changes that characterize the leptin-deficient state. The proposed studies focus on the neuroendocrine, autonomic, and metabolic changes that characterize the reduced-obese individual, and the effects on these phenotypes of restoration of circulating concentrations of leptin to levels present prior to weight loss. Healthy lean and overweight subjects are admiited to the General Clinical Research Center at Columbia University Medical College and placed on a liquid formula diet. Calories are adjusted until weight is stable and then subjects undergo testing of neuroendocrine, autonomic, and metabolic function. All subjects undergo an in-patient 10% weight reduction. Subjects are studied in a single blind placebo control design in which they are studied at usual weight and while maintaining a 10% reduced weight. At either usual weight or reduced state subjects undergo a single blind crossover placebo/control study in which they receive placebo,lepin injections while on an isocaloric diet either at usual weight or following a 10% weight loss. Leptin injections are given in doses that restored 8AM circulating leptin concentrations to those present at initial body weight. During each of these study periods, subjects will undergo detailed evaluation of 1.) energy expenditure (11 day differential excretion of heavy isotopes of water, indirect calorimetry for resting energy expenditure, non-resting energy expenditure, and thermic effect of feeding, time spent in physical activity); 2.) autonomic nervous system tone (serial blockade of sympathetic and parasympathetic inputs, heart rate variability analyses, and urinary catecholamine excretion); 3.) hypothalamic-pituitary-thyroid, -adrenal and -gonadal, axis function; 4.) adipose tissue gene expression; 5.) other molecules (e.g., adiponectin, ghrelin, PYY) that may influence neuroendocrine and metabolic function. We predict that leptin administration will reverse the metabolic, autonomic, and neuroendocrine phenotypes characterizing the weight-reduced state. The results of these studies will further delineate the physiology of body weight regulation and of leptin.

  Eligibility

Ages Eligible for Study:   19 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria: Healthy lean or overweight males and females who have sustained their current weight for at least 6 months.

-

Exclusion Criteria:Pregnancy, any illness or chronic medication that affect energy expenditure, neuroendocrine function,autonomic function or that would impair ability to tolerate a prolonged hospital stay including rapid weight reduction and vigorous exercise.

-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00265980

Locations
United States, New York
Columbia University Medical College/The New York Presbyterian Medical Center
New York, New York, United States, 10032
Sponsors and Collaborators
Columbia University
Investigators
Principal Investigator: Rudolph L Leibel, M.D. Columbia University
Study Director: Michael Rosenbaum, M.D. Columbia University
  More Information

Publications:
Responsible Party: Rudolph L. Leibel, Professor of Pediatrics and Medicine, Columbia University
ClinicalTrials.gov Identifier: NCT00265980     History of Changes
Other Study ID Numbers: AAAA5988, R01DK064773
Study First Received: December 14, 2005
Last Updated: July 31, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Columbia University:
Leptin
Obesity
Energy
Autonomics
Neuroendocrine

Additional relevant MeSH terms:
Obesity
Weight Loss
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
Body Weight Changes

ClinicalTrials.gov processed this record on October 16, 2014